CS
JBIO

Credit Suisse’s Jade Biosciences JBIO Stock Holding History

Credit Suisse’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-259
Closed -$266K – 3299
2022
Q4 		$266K Buy
259
+258
+25,800% +$187K ﹤0.01% 3091
2022
Q3 		$1K Buy
+1
New +$668 ﹤0.01% 3807
2022
Q2 		– Hold
0
– – – 3923

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Credit Suisse's JBIO Position: Q1 2023 in Review

Credit Suisse sold out of Jade Biosciences (JBIO) in Q1 2023, closing a stake of 259 shares — an estimated $266K sold.

Credit Suisse first reported a position in JBIO in Q3 2022 and held it in 2 quarters. The position peaked at $266K in Q4 2022. 64 funds tracked by Wall St. Rank hold JBIO as of Q1 2023.

  • Credit Suisse reported no remaining Jade Biosciences position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 259 Jade Biosciences shares in Q1 2023, an estimated $266K.
  • Credit Suisse first reported a position in Jade Biosciences in Q3 2022 and held it in 2 quarters.
  • Credit Suisse's Jade Biosciences position peaked at $266K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.